Zidovudine (AZT)
The first NRTI (Nucleoside Reverse Transcriptase Inhibitor) approved for HIV. It blocks the virus's ability to replicate its DNA.
Dosage by Body Weight
For neonates (prevention): 4 mg/kg twice daily for 4–6 weeks. For treatment: weight-band based.
- Body Weight
- 4-9 kg
- Dose
- 60 mg (6 ml syrup)
- Frequency
- Twice daily
- Tracking Notes
- Monitor for anemia (low red blood cell count).
- Body Weight
- 10-14 kg
- Dose
- 100 mg
- Frequency
- Twice daily
- Tracking Notes
- Commonly part of a three-drug regimen.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| 4-9 kg | 60 mg (6 ml syrup) | Twice daily | Monitor for anemia (low red blood cell count). |
| 10-14 kg | 100 mg | Twice daily | Commonly part of a three-drug regimen. |
Formulation
SyrupCapsuleInjection
Purpose
Treatment of HIV-1 infection and prevention of mother-to-child transmission.
Generic Name
Zidovudine
Branded Drug Names
Zidovudine (AZT) is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
- Retrovir
- Zidovir
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.
Alternatives
LamivudineTenofovir